Effectiveness and Safety of Different Oral Anticoagulants with P-glycoprotein/CYP3A4 Inhibitors: A Network Meta-analysis

荟萃分析 CYP3A4型 医学 药理学 梅德林 化学 内科学 生物化学 新陈代谢 细胞色素P450
作者
Siyu Yang,Ye Xu,Yang Zhang,Dandan Li,Xingang Li,Xingang Li
出处
期刊:Current Pharmaceutical Design [Bentham Science Publishers]
卷期号:30 (15): 1167-1177 被引量:1
标识
DOI:10.2174/0113816128293940240315073345
摘要

BACKGROUND: Metabolism of oral anticoagulants (OAC) is affected by P-glycoprotein (P-gp)/ CYP3A4 enzyme. However, the P-gp/CYP3A4 inhibitors are unavoidably used with OACs. METHODS: Medline, Cochrane, and Embase were systematically searched for randomized controlled trials and cohort studies from inception till 23rd November, 2022 to assess the safety and effectiveness of OACs when concomitantly used with P-gp/CYP3A4 inhibitors. The primary outcomes were major bleeding and gastrointestinal (GI) bleeding. Secondary outcomes were stroke/systemic embolism (SE), all-cause mortality, any bleeding as well as intracranial hemorrhage (ICH). We estimated summary odds ratios (OR) with 95% credible intervals (CI) using pairwise and network meta-analysis with random effects. RESULTS: A total of 11 studies involving 37,973 patients were included. When concomitantly used with P-pg/ CYP3A4 inhibitors, network meta-analysis indicated that dabigatran, apixaban, and edoxaban were associated with significantly lower risk of major bleeding compared to rivaroxaban, with ORs of 0.56, 0.51 and 0.48, respectively. Rivaroxaban and dabigatran were associated with a significantly increased risk of GI bleeding than warfarin, apixaban and edoxaban. Dabigatran and apixaban were linked with significantly lower risk of any bleeding compared with warfarin (ORs were 0.75 and 0.68, respectively) or rivaroxaban (ORs were 0.67 and 0.60, respectively). Apixaban (OR 0.32) and edoxaban (OR 0.35) were associated with a lower risk of ICH compared with warfarin. There was no difference between any OACs in terms of stroke/SE or all-cause mortality. CONCLUSION: When concomitantly used with P-gp/CYP3A4 inhibitors, apixaban and edoxaban were associated with a lower risk of bleeding, though no significant difference in effectiveness was observed among all OACs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酱酱完成签到 ,获得积分10
刚刚
刚刚
柚子发布了新的文献求助10
刚刚
1秒前
Xk发布了新的文献求助10
4秒前
小蘑菇的应助被kitten采纳,获得10
6秒前
yshog完成签到,获得积分10
7秒前
yuan完成签到,获得积分10
7秒前
istor发布了新的文献求助10
7秒前
7秒前
布式鹿炽完成签到,获得积分10
8秒前
9秒前
柚子完成签到,获得积分20
9秒前
Cyber_relic完成签到,获得积分10
9秒前
无私鹤轩发布了新的文献求助10
10秒前
无私鹤轩发布了新的文献求助10
10秒前
风吹麦浪发布了新的文献求助10
10秒前
无私鹤轩发布了新的文献求助10
11秒前
无私鹤轩发布了新的文献求助10
11秒前
无私鹤轩发布了新的文献求助10
11秒前
Spike完成签到,获得积分10
11秒前
无私鹤轩发布了新的文献求助10
12秒前
无私鹤轩发布了新的文献求助10
12秒前
12秒前
无私鹤轩发布了新的文献求助10
12秒前
信仰完成签到,获得积分10
13秒前
容止完成签到,获得积分10
14秒前
汉堡包的应助被尼古丁真采纳,获得10
14秒前
mu发布了新的文献求助10
15秒前
haha完成签到,获得积分10
15秒前
xj发布了新的文献求助10
16秒前
李佳完成签到,获得积分10
16秒前
yang的应助被科研通管家采纳,获得10
18秒前
fantasy的应助被科研通管家采纳,获得10
18秒前
科研通AI65的应助被科研通管家采纳,获得10
18秒前
元吉的应助被科研通管家采纳,获得10
19秒前
无极微光的应助被科研通管家采纳,获得20
19秒前
Danger完成签到 ,获得积分10
19秒前
SciGPT的应助被科研通管家采纳,获得10
19秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191072
求助须知:如何正确求助?哪些是违规求助? 9578083
关于积分的说明 21856545
捐赠科研通 7790236
什么是DOI,文献DOI怎么找? 3436520
关于科研通互助平台的介绍 2560326
邀请新用户注册赠送积分活动 2483237